BusinessVoyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsBy Nasdaq OMXMar 14, 2018, 11:02 AM UTC
BusinessVoyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s DiseaseBy Nasdaq OMXMar 9, 2018, 12:02 PM UTC
BusinessVoyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative DiseasesBy Nasdaq OMXFeb 20, 2018, 12:01 PM UTC
BusinessVoyager Therapeutics Announces CEO Succession Plan for 2018By Nasdaq OMXJan 31, 2018, 9:05 PM UTC
BusinessVoyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s DiseaseBy Nasdaq OMXJan 23, 2018, 12:04 PM UTC
BusinessVoyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D DayBy Nasdaq OMXNov 16, 2017, 9:45 PM UTC
BusinessVoyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate HighlightsBy Nasdaq OMXNov 2, 2017, 8:01 PM UTC
BusinessVoyager Therapeutics Announces Update to Parkinson’s Disease ProgramBy Nasdaq OMXOct 30, 2017, 8:01 PM UTC
